Institut Pasteur

Centre National De La Recherche Scientifique

Commissariat &#xc0; L'&#xc9;nergie Atomique Et Aux &#xc9;nergies Alternatives

F. Hoffmann-la Roche Ag

Institut National De La Sante Et De La Recherche Medicale

Pierre Lafaye

Sylvie Bay

Fiona Grueninger

Christian Czech

Charles Duyckaerts

Matthias Vandesquille

Tengfei Li

Marc Dhenain

Benoit Delatour

Jean-Pierre Bourgeois

Francois Rougeon

Sylvie Van Der Werf

Monique Lafon

Christophe Prehaud

Nicolas Escriou

Jacques Bellalou

Caroline Demeret

Stéphane Petres

Pierre-Emmanuel Ceccaldi

François Rougeon

Philippe Afonso

Benoît Delatour

The invention relates to the diagnosis of a SARS-associated coronavirus, such as a SARS-CoV-2 infection and SARS-CoV-1 infection, using the N_SARS-CoV-1 and N_SARS-CoV-2 proteins and antibodies binding to these proteins. The invention reagents, methods and kits for the detection of a SARS-associated coronavirus.

Severe acute respiratory syndrome (SARS)—associated coronavirus diagnostics

The invention relates to the diagnosis of a SARS-associated coronavirus, such as a SARS CoV-2 infection and SARS-CoV infection, using the SARS-CoV and SARS-CoV-2 nucleocapsid proteins and antibodies binding to these proteins. The invention encompasses reagents, methods and kits for the detection of a SARS-associated coronavirus.

Severe acute respiratory syndrome (SARS)-associated coronavirus diagnostics

The invention is in the domain of delivery of molecules to brain cells across the blood-brain barrier. The invention relates to a novel polypeptide-based carrier that allows the efficient delivery of an effector peptide, to neuron cells across the blood-brain barrier, and to methods for the production and testing of such carrier, including a model for testing the capacity of such molecule to cross the blood-brain barrier and/or the toxicity of molecules on the blood brain barrier and/or the capacity of molecules that have crossed to target human brain cells (e/g. neurons, astrocytes and microglial cells).

Nanobodies suitable for neuron regeneration therapy

The present invention relates to variable domains of a camelid heavy-chain antibodies directed against a phosphorylated tau protein and conjugates thereof. The present invention also relates to the use of these domains or conjugates for treating or diagnosing disorders mediated by neurofibrillary tangles, neuropil threads or dystrophic neurites, such as tauopathies.

Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof

Severe acute respiratory syndrome (SARS)&#x2014;associated coronavirus diagnostics

The present invention relates to an oligopeptide and conjugates thereof. The present invention also relates to the use of these oligopeptide conjugates for treating or diagnosing disorders mediated by amyloid &#x3b2; deposits. Finally, the present invention also relates to a coupling method for obtaining oligopeptide coupled with a substance of interest (functional conjugates).

Oligopeptide and methods for producing conjugates thereof

The invention is in the domain of delivery of molecules to brain cells across the blood-brain barrier. The invention relates to a novel polypeptide-based carrier that allows the efficient delivery of an effector peptide, to neuron cells across the blood-brain barrier, and to methods for the production and testing of such carrier, including a model for testing the capacity of such molecule to cross the blood-brain barrier and/or the toxicity of molecules on the blood brain barrier and/or the capacity of molecules that have crossed to target human brain cells (e.g. neurons, astrocytes and microglial cells).

In vitro blood-brain barrier model

Use of a variable fragment (VHH antibody) of a camelid single-chain antibody for the preparation of a peptide vector for delivering a substance of interest across the blood-brain barrier or into a cell.

Use of VHH antibodies for the preparation of peptide vectors for delivering a substance of interest and their applications

The present invention relates to the use of variable domains of camelid heavy-chain antibodies (VHH domains) directed against an intracellular target and having an isoelectric point of at least 8.5, for targeting said intracellular target or for the preparation of a peptide vector. Particularly, it concerns VHH domains directed against a glial fibrillary acidic protein and uses thereof for preparing therapeutic or diagnostic agents.

Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins

The present invention relates to variable domain of a camelid heavy-chain antibodies directed to amyloid &#x3b2; and conjugates thereof. The present invention also relates to the use of these antibody conjugates for treating or diagnosing disorders mediated by amyloid &#x3b2; deposits.

Camelid single-domain antibody directed against amyloid beta and methods for producing conjugates thereof

VHH antibodies used as peptide vectors for delivering a substance of interest

Growing community of inventors

Malakoff, France

Pierre Lafaye